Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-PHYLLIN vs AMINOPHYLLINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.
Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., COPD, emphysema, chronic bronchitis),Off-label: Apnea of prematurity,Off-label: Adjunctive therapy in acute asthma exacerbations (rarely used)
Treatment of acute bronchospasm in asthma and COPD,Treatment of apnea of prematurity,Off-label: adjunctive therapy in COPD exacerbations, status asthmaticus
Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.
Terminal elimination half-life is approximately 3-8 hours in adults (non-smokers, healthy), 1-5 hours in smokers, and 20-30 hours in neonates. Clinical context: Half-life is prolonged in hepatic cirrhosis, heart failure, and with certain drug interactions (e.g., cimetidine, ciprofloxacin).
Adults: 7-9 hours (nonsmokers), 4-5 hours (smokers), 10-20 hours (neonates, hepatic impairment, CHF).
Primarily hepatic via CYP450 enzymes: CYP1A2, CYP2E1, CYP3A4; metabolite: 1,3-dimethyluric acid. Approximately 10% excreted unchanged in urine.
Hepatic metabolism via CYP1A2 and xanthine oxidase; demethylation and oxidation yield active metabolites (caffeine and 3-methylxanthine).
Renal: ~10% unchanged; hepatic metabolism accounts for ~90% of elimination, with metabolites excreted in urine. Fecal: <5%.
Renal: ~10% unchanged; hepatic metabolism (N-demethylation, oxidation) accounts for >80% of elimination; <1% fecal.
Approximately 40% bound to albumin; binding is saturable and decreased in neonates, hepatic disease, and acidosis.
Approximately 40-60% bound to albumin in adults; lower in neonates (20-30%) and patients with hepatic disease.
0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Distributes evenly into body water and highly perfused tissues; Vd increased in premature infants and decreased in obesity.
0.3-0.7 L/kg (average 0.45 L/kg); increased in neonates, cirrhosis, and CHF.
Oral immediate-release: 96-100%; oral sustained-release (Slo-Phyllin): 90-100% relative to immediate-release; rectal: variable (~80-100% for enema); IV: 100%.
Oral: ~100% (well-absorbed); Rectal: ~80-100% (variable); IM: ~100% (avoid due to pain and unpredictable absorption).
No specific dose adjustment is required for renal impairment. However, monitoring serum concentrations is recommended due to altered clearance in severe renal failure (GFR <10 m L/min).
No specific dose adjustment required based on GFR; monitor theophylline levels closely in renal impairment.
Child-Pugh Class B or C: Reduce dose by 50% and monitor serum concentrations closely. Avoid use in severe hepatic impairment if possible.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 50-75% or consider alternative.
Starting dose: 5 mg/kg/day orally in divided doses every 6 hours (immediate-release) or every 12 hours (sustained-release). Titrate based on serum concentrations, targeting 5-15 mcg/m L. Maximum dose: 24 mg/kg/day or 900 mg/day, whichever is less.
Oral: 5 mg/kg/dose every 6 hours; IV loading: 5-6 mg/kg; maintenance: 0.5-0.9 mg/kg/hour for ages 6 months-9 years, 0.4-0.5 mg/kg/hour for ages 9-16 years.
Start at low end of dosing range (e.g., 200-300 mg/day sustained-release). Monitor serum concentrations carefully as clearance is reduced in elderly patients, increasing risk of toxicity.
Reduce initial dose by 50% (e.g., 0.2-0.3 mg/kg/hour IV) due to decreased clearance; monitor serum theophylline levels and titrate slowly.
No FDA boxed warning.
No FDA boxed warning exists; however, use caution in patients with acute myocardial injury due to potential arrhythmias.
Concurrent illness (fever, influenza), hepatic impairment, elderly, and smoking alter metabolism; narrow therapeutic index (10-20 mcg/m L); monitor serum levels; risk of seizures, arrhythmias, and death with toxicity; reduce dose with CYP1A2 inhibitors (cimetidine, fluoroquinolones, macrolides) or inducers (smoking, rifampin, phenytoin); caution in peptic ulcer disease, seizure disorders, cardiac arrhythmias.
Narrow therapeutic index requiring monitoring of serum theophylline levels; increased seizure risk at high concentrations; arrhythmia risk; caution in heart failure, hepatic impairment, and elderly.
Hypersensitivity to theophylline or any component,Pre-existing arrhythmia (especially tachyarrhythmias),Active seizure disorder not adequately controlled
Hypersensitivity to aminophylline, theophylline, ethylenediamine; uncontrolled arrhythmias; active seizure disorder; peptic ulcer; severe hypertension.
Avoid high-fat meals as they may alter absorption of sustained-release preparations. Limit caffeine-containing foods and beverages. Avoid charcoal-broiled foods, which can increase metabolism.
Avoid high-fat meals which can decrease absorption and lead to variable serum levels. Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase theophylline toxicity and side effects. Charcoal-broiled foods and a high-protein, low-carbohydrate diet may increase clearance of theophylline. Consistently maintain dietary habits to avoid fluctuations in theophylline levels.
Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester exposure is not associated with major congenital malformations. Third trimester use may lead to transient neonatal apnea, jitteriness, or tachycardia due to placental transfer. No increased risk of preterm birth or low birth weight has been consistently demonstrated.
Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the first trimester, limited data do not indicate a significant increase in major malformations, but the drug should be used only if clearly needed. In the second and third trimesters, theophylline may cause fetal tachycardia, jitteriness, and irritability if maternal levels are high. Near term, accumulation of theophylline in the fetus may lead to neonatal withdrawal (irritability, apnea) and transient tachycardia. Risk is dose-dependent and more pronounced at serum levels >15 mcg/m L.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach therapeutic concentrations if maternal doses are high. Breastfeeding is generally considered compatible, but monitor the infant for signs of theophylline toxicity (e.g., irritability, insomnia, tachycardia).
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. Infant exposure is estimated to be 1–10% of the maternal weight-adjusted dose. Premature infants or those with impaired clearance are at risk for accumulation and toxicity (irritability, jitteriness, feeding intolerance). Breastfeeding is generally considered acceptable if maternal serum levels are within therapeutic range (5-15 mcg/m L) and the infant is monitored for signs of theophylline toxicity. American Academy of Pediatrics classifies theophylline as compatible with breastfeeding, but caution is advised.
Pregnancy may decrease theophylline clearance by 20-30%, particularly in the third trimester, due to reduced hepatic metabolism. Dose adjustments may be needed to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; reduce dose accordingly to avoid toxicity.
Pregnancy increases the clearance of theophylline by approximately 20-30% due to increased volume of distribution and hepatic metabolism (especially in the second and third trimesters). Doses may need to be increased by 20-30% to maintain therapeutic serum levels. Frequent monitoring of serum theophylline levels (every 1-2 weeks) is recommended to guide dose adjustments. Postpartum, clearance returns to prepregnancy levels within 2-3 months, so doses should be reduced to avoid toxicity.
Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Adjust dose in patients with heart failure, liver disease, or on CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Do not crush or chew sustained-release tablets. Cigarette smoking induces metabolism, requiring higher doses.
1. Aminophylline is a bronchodilator that is a combination of theophylline and ethylenediamine; the ethylenediamine component may cause allergic reactions in sensitive individuals. 2. Monitor serum theophylline levels closely (therapeutic range: 10-20 mcg/m L); toxicity can occur at levels >20 mcg/m L with symptoms including nausea, vomiting, tachycardia, and seizures. 3. Use with caution in patients with severe hypoxemia, and treat with diltiazem or benzodiazepines for seizures if they occur. 4. Aminophylline can cause significant drug interactions, particularly with cimetidine, fluoroquinolones, and macrolide antibiotics which increase theophylline levels. 5. In acute asthma exacerbations, aminophylline is typically reserved for cases not responding to inhaled beta-agonists and corticosteroids due to narrow therapeutic index.
Take this medication exactly as prescribed, usually every 8-12 hours.,Do not crush or chew the tablets; swallow them whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, or irregular heartbeat.,Do not change brands or formulations without consulting your doctor.
Take this medication exactly as prescribed; do not chew or crush extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects such as nervousness and palpitations.,Notify your doctor immediately if you experience nausea, vomiting, irregular heartbeats, or seizures.,Do not smoke or stop smoking without consulting your doctor, as smoking affects how this medication works.,Keep a record of peak flow readings as directed by your healthcare provider.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-PHYLLIN vs AMINOPHYLLINE, answered by our medical review team.
SLO-PHYLLIN is a Xanthine Bronchodilator that works by SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.. AMINOPHYLLINE is a Xanthine Bronchodilator that works by Aminophylline is a bronchodilator and respiratory stimulator that acts as a non-selective phosphodiesterase inhibitor, increasing cyclic AMP levels, and as an adenosine receptor antagonist. It also enhances diaphragmatic contractility and mucociliary clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-PHYLLIN and AMINOPHYLLINE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-PHYLLIN is: Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AMINOPHYLLINE is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if no recent theophylline). Maintenance: 0.4-0.6 mg/kg/hour IV continuous infusion; oral: 300-600 mg/day divided every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-PHYLLIN and AMINOPHYLLINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-PHYLLIN is classified as Category C. Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester expos. AMINOPHYLLINE is classified as Category C. Aminophylline is a bronchodilator containing theophylline and ethylenediamine. Theophylline crosses the placenta and fetal serum concentrations approximate maternal levels. In the . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.